410 Thames Valley Park Drive
Reading,
Berkshire
RG6 1PT
United Kingdom

December 2023

DIRECT HEALTHCARE PROFESSIONAL COMMUNICATION
VERORAB, powder and solvent for suspension for injection - PLGB 46602/0029
Interim Supply of UK Stock in Standard Export Packaging (Standard Export Packs) to Mitigate Supply Disruption

Dear Healthcare Professional,

We have been alerted to an upcoming supply disruption with the current sole supplier of Rabies vaccine in the UK. In order to prevent an out-of-stock situation and to ensure continuity of supply of rabies vaccine to GP surgeries and travel clinics in the UK, Sanofi has obtained approval from the MHRA to supply its product Verorab, PLGB 46602/0029, in Standard Export Packs (Batch W1B091V; Expiry May 2025; 10,000 doses), which is expected to be available to the UK market from early 2024.

Please note the following:

- This product is considered licensed in the UK.
- Please note the following points regarding the export pack presentation:
    - **The presentation is a single dose containing powder and solvent for suspension for injection, in a box of 10.**
    - Text in three languages (English, French and Spanish) is included on the Carton and label components of the Standard Export Pack; text in two languages (English and French) on the PIL component of the Standard Export Park. An image of the Standard Export Pack is provided below.

To access the PIL for the PLGB licence, please refer to https://mhraproducts4853.blob.core.windows.net/docs/7a01e184614db9dfd4cb381c7db0c08292c98439 or contact the company contact point (see below).

The MHRA has approved this product under a batch specific variation to the PLGB marketing authorisation.

Please ensure all relevant staff are made aware of the content of this letter and that the information is communicated to the patients.

Verorab Standard Export Packaging



Call for reporting

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Sanofi drug safety department on Tel: 0800 0902 314. Alternatively, send via email to UKdrugsafety@sanofi.com .

Company contact point

If you have any questions about this letter or would like more information about VERORAB, please contact Sanofi Medical Information Department on 0800 035 2525 or email **uk-medicalinformation@sanofi.com**.

Yours faithfully,

To be signed at approval

Femy Amin
Medical Lead (Vaccines)